SMH
PDLI

Sanders Morris Harris’s PDL BioPharma, Inc. PDLI Stock Holding History

Sanders Morris Harris’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-14,132
Closed -$44K – 244
2016
Q2 		$44K Buy
+14,132
New +$47.1K 0.01% 235

Other funds holding PDLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $70.2B AUM 29.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Sanders Morris Harris's PDLI Position: Q3 2016 in Review

Sanders Morris Harris sold out of PDL BioPharma, Inc. (PDLI) in Q3 2016, closing a stake of 14,132 shares — an estimated $44K sold.

Sanders Morris Harris first reported a position in PDLI in Q2 2016 and held it in 1 quarter. The position peaked at $44K in Q2 2016. 197 funds tracked by Wall St. Rank hold PDLI as of Q3 2016.

  • Sanders Morris Harris reported no remaining PDL BioPharma, Inc. position as of Q3 2016 after selling out during the quarter.
  • Sanders Morris Harris sold 14,132 PDL BioPharma, Inc. shares in Q3 2016, an estimated $44K.
  • Sanders Morris Harris first reported a position in PDL BioPharma, Inc. in Q2 2016 and held it in 1 quarter.
  • Sanders Morris Harris's PDL BioPharma, Inc. position peaked at $44K in Q2 2016.
  • 197 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2016.

Based on Sanders Morris Harris's 13F filing for Q3 2016, filed 24 Oct 2016.